Press

10

2014

World Allergy Organization Journal

Allergic diseases and asthma: a global public health concern and a call to action

Read more
CloseX

Allergic diseases and asthma: a global public health concern and a call to action

Panwankar

The prevalence of allergic diseases and asthma are increasing worldwide, particularly in low and middle income countries. Moreover, the complexity and severity of allergic diseases, including asthma, continue to increase especially in children and young adults, who are bearing the greatest burden of these trends.

Read the full article here

20

2018

AMA Pediatrics

Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood

Read more
CloseX

Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood

Mitre et al

In this cohort study of 792,130 children, the hazard of developing an allergic disease was significantly increased in those who had received acid-suppressive medications or antibiotics during the first 6 months of life.

Read the full article here

50

2015

US Nat’l Library of Medicine NIH

Microbiota in allergy and asthma and the emerging relationship with the gut microbiome

Read more
CloseX

Microbiota in allergy and asthma and the emerging relationship with the gut microbiome

Fujimura & Lynch

Asthma and atopy, classically associated with hyper-activation of the T helper 2 (Th2) arm of adaptive immunity, are among the most common chronic illnesses worldwide. Emerging evidence relates atopy and asthma to the composition and function of the human microbiome, the collection of microbes that reside in and on and interact with the human body.

Read the full article here

60

2016

Nature Medicine

Neonatal gut microbota associates with childhood multisensitized atopy and T cell differentiation

Read more
CloseX

Neonatal gut microbota associates with childhood multisensitized atopy and T cell differentiation

Fujimura et al

Gut microbiota bacterial depletions and altered metabolic activity at 3 months are implicated in childhood atopy and asthma. We hypothesized that compositionally distinct human neonatal gut microbiota (NGM) exist, and are differentially related to relative risk (RR) of childhood atopy and asthma.

Read the full article here

70

2018

Nature Communications

Delayed gut microbiota development in high-risk-for-asthma infants is temporarily modifiable by Lactobacillus supplementation

Read more
CloseX

Delayed gut microbiota development in high-risk-for-asthma infants is temporarily modifiable by Lactobacillus supplementation

Durack et al

Gut microbiota dysbiosis and metabolic dysfunction in infancy precedes childhood atopy and asthma development. Here we examined gut microbiota maturation over the first year of life in infants at high risk for asthma (HR), and whether it is modifiable by early-life Lactobacillus supplementation.

Read the full article here

80

Winner, 2017 “Bugs, Drugs and Beyond Quickfire Challenge” sponsored by Johnson & Johnson Innovation, JLABS

Read more
CloseX

Winner, 2017 “Bugs, Drugs and Beyond Quickfire Challenge” sponsored by Johnson & Johnson Innovation, JLABS

The microbiome represents a dramatically new frontier in medicine, providing a vast array of potential targets and mechanisms through which we may harness the body’s naturally-occurring responses to treat disease and maintain health. Join the Janssen Human Microbiome Institute , JLABS @ SSF and Stanford for a one-day forum to explore the ways in which innovators from San Francisco and beyond are harnessing the human microbiome and advancing novel therapeutics, diagnostics and other health products.

Read more

90

Fellows All-Star Team (FAST) Advisory Program, 2017

Read more
CloseX

Fellows All-Star Team (FAST) Advisory Program, 2017

Designed to help promising life science startups prove their business model and develop a compelling commercialization strategy, the acclaimed FAST program draws on a high-level team of advisors to provide experience, contacts and counsel to the selected participants.

Since launching in Fall 2013, FAST program cycles have generated over 6200 advisory hours valued at over $1,400,000 for the 56 companies who have been through the program. Since participating in FAST, these companies have raised $650 million and created 258 new jobs, more than tripling their workforce. Fifteen of these companies have secured Series A investments, 9 have concluded strategic partnerships and 5 have successfully exited.

The FAST Advisory Program provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement and business development specialists) will advise selected Fellows during a ten-to-twelve week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.

Read more

100

Springboard Enterprises’ Health Innovation Hub, 2018

Read more
CloseX

Springboard Enterprises’ Health Innovation Hub, 2018

Siolta Therapeutics selected for Springboard’s health innovation hub, joins network of over 700 seasoned entrepreneurs.

Siolta Therapeutics is one of just 15 life science companies selected this year for the Springboard Enterprises’ Health Innovation Hub. They join over 700 experienced “been there, run that” entrepreneurs who make up the Springboard Expert Network. This year’s cohort recently convened in Boston, MA, from April 25 – 27 for the Health Hub Bootcamp. The three-day Bootcamp is just the first step of the three-month program, during which selected companies receive tailored advising from a range of experts. The accelerator program culminates in July with a final pitch to investors and stakeholders. Companies recruited and qualified by Springboard’s network of advisors are among the most promising companies led by some of the most talented and accomplished women entrepreneurs.


“Investors say they like to bet on the jockey not the horse,” said Kay Koplovitz, CEO of Koplovitz and Co. and Chairman of Springboard Enterprises, “and this year we are betting our human capital on an impressive group of experienced entrepreneurial women who will not only benefit from the talent in our expert network, but also add immeasurably to it.”

Since 2000, Springboard has become a human capital powerhouse connecting growth stage companies with investors, advisors and lucrative business opportunities. Siolta Therapeutics joins the ranks of globally recognized brands including Achillion, Xenogen, ViaCord, ZipCar, Constant Contact, and MinuteClinic.

Contact: Mary Jackson, mary@sb.com

110

Jan 22 - 24 2018

Silicon Valley, CA

Precision Medicine World Conference (PMWC) 2018

More Info
CloseX

Precision Medicine World Conference (PMWC) 2018

Jan 22 - 24 2018

The Precision Medicine World Conference (PMWC), in its 13th installment, will take place in Silicon Valley on January 22-24, 2018. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Register Here